Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Plaque, Atherosclerotic | 83 | 2024 | 1550 | 12.210 |
Why?
|
Coronary Artery Disease | 113 | 2024 | 6569 | 7.520 |
Why?
|
Coronary Vessels | 69 | 2024 | 3124 | 6.290 |
Why?
|
Coronary Angiography | 80 | 2024 | 4541 | 4.160 |
Why?
|
Endothelium, Vascular | 37 | 2023 | 4428 | 4.030 |
Why?
|
Coronary Circulation | 31 | 2024 | 1617 | 3.950 |
Why?
|
Stress, Mechanical | 31 | 2023 | 1680 | 3.440 |
Why?
|
Myocardial Ischemia | 42 | 2024 | 2139 | 3.430 |
Why?
|
Shear Strength | 7 | 2019 | 160 | 2.390 |
Why?
|
Angina Pectoris | 29 | 2023 | 957 | 2.270 |
Why?
|
Electrocardiography, Ambulatory | 35 | 2017 | 582 | 2.170 |
Why?
|
Hemodynamics | 22 | 2024 | 4199 | 1.800 |
Why?
|
Angina, Unstable | 22 | 2022 | 893 | 1.570 |
Why?
|
Ultrasonography, Interventional | 21 | 2024 | 1524 | 1.360 |
Why?
|
Angioplasty, Balloon, Coronary | 16 | 2021 | 1724 | 1.340 |
Why?
|
Coronary Restenosis | 6 | 2019 | 396 | 1.310 |
Why?
|
Coronary Disease | 34 | 2020 | 5919 | 1.270 |
Why?
|
Acute Coronary Syndrome | 16 | 2024 | 2194 | 1.270 |
Why?
|
Myocardial Revascularization | 9 | 2022 | 796 | 1.210 |
Why?
|
Coronary Stenosis | 10 | 2021 | 802 | 1.150 |
Why?
|
Stents | 10 | 2021 | 3200 | 1.140 |
Why?
|
Acetanilides | 5 | 2013 | 169 | 1.120 |
Why?
|
Disease Progression | 47 | 2024 | 13677 | 1.090 |
Why?
|
Atherosclerosis | 13 | 2023 | 3431 | 1.010 |
Why?
|
Exercise Test | 27 | 2017 | 2187 | 0.930 |
Why?
|
Predictive Value of Tests | 44 | 2024 | 15471 | 0.930 |
Why?
|
Myocardial Infarction | 65 | 2024 | 11521 | 0.920 |
Why?
|
Arrhythmias, Cardiac | 9 | 2023 | 2258 | 0.920 |
Why?
|
Models, Cardiovascular | 9 | 2020 | 983 | 0.890 |
Why?
|
Neointima | 4 | 2016 | 133 | 0.870 |
Why?
|
Nifedipine | 15 | 2000 | 220 | 0.830 |
Why?
|
Regional Blood Flow | 6 | 2018 | 1502 | 0.760 |
Why?
|
Piperazines | 5 | 2013 | 2553 | 0.680 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2023 | 3253 | 0.640 |
Why?
|
Electrodes, Implanted | 1 | 2023 | 841 | 0.630 |
Why?
|
Humans | 275 | 2024 | 768887 | 0.620 |
Why?
|
Stress, Physiological | 6 | 2017 | 1410 | 0.600 |
Why?
|
Drug-Eluting Stents | 4 | 2016 | 681 | 0.580 |
Why?
|
Imaging, Three-Dimensional | 8 | 2020 | 4077 | 0.560 |
Why?
|
Microcirculation | 3 | 2018 | 1281 | 0.550 |
Why?
|
Tomography, Optical Coherence | 10 | 2024 | 2957 | 0.540 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2020 | 346 | 0.540 |
Why?
|
Heptanoic Acids | 4 | 2007 | 344 | 0.510 |
Why?
|
Rupture, Spontaneous | 6 | 2024 | 365 | 0.510 |
Why?
|
Arteries | 4 | 2021 | 1126 | 0.510 |
Why?
|
Vasodilator Agents | 6 | 2006 | 990 | 0.480 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 5 | 2024 | 1232 | 0.470 |
Why?
|
Heart Rate | 23 | 2011 | 4217 | 0.460 |
Why?
|
Vehicle Emissions | 4 | 2007 | 651 | 0.440 |
Why?
|
Middle Aged | 144 | 2024 | 223740 | 0.430 |
Why?
|
Hyperplasia | 1 | 2016 | 1154 | 0.430 |
Why?
|
Adrenergic beta-Antagonists | 14 | 2013 | 1243 | 0.420 |
Why?
|
Risk Factors | 59 | 2024 | 74971 | 0.420 |
Why?
|
Male | 163 | 2024 | 365249 | 0.420 |
Why?
|
Electrocardiography | 34 | 2011 | 6413 | 0.410 |
Why?
|
Procollagen | 1 | 2013 | 189 | 0.410 |
Why?
|
Endothelium | 1 | 2015 | 768 | 0.410 |
Why?
|
Diabetic Angiopathies | 4 | 2018 | 806 | 0.390 |
Why?
|
Registries | 24 | 2024 | 8384 | 0.390 |
Why?
|
Matrix Metalloproteinases | 2 | 2013 | 393 | 0.390 |
Why?
|
Sodium Channel Blockers | 1 | 2013 | 173 | 0.390 |
Why?
|
Cholesterol, LDL | 10 | 2019 | 2402 | 0.390 |
Why?
|
Aged | 108 | 2024 | 171790 | 0.390 |
Why?
|
Pyrroles | 4 | 2007 | 1126 | 0.380 |
Why?
|
Amlodipine | 4 | 2006 | 84 | 0.370 |
Why?
|
Aviation | 1 | 2011 | 49 | 0.370 |
Why?
|
Sodium Channels | 1 | 2013 | 341 | 0.370 |
Why?
|
Female | 152 | 2024 | 397464 | 0.360 |
Why?
|
Computer Simulation | 6 | 2016 | 6289 | 0.350 |
Why?
|
Enzyme Inhibitors | 2 | 2011 | 3724 | 0.350 |
Why?
|
Allopurinol | 1 | 2011 | 202 | 0.340 |
Why?
|
Air Pollution | 7 | 2010 | 2367 | 0.330 |
Why?
|
Collagen Type I | 1 | 2013 | 620 | 0.330 |
Why?
|
Risk Assessment | 25 | 2024 | 24330 | 0.330 |
Why?
|
Coronary Thrombosis | 3 | 2020 | 440 | 0.330 |
Why?
|
Stress, Psychological | 9 | 2022 | 4542 | 0.330 |
Why?
|
Anticholesteremic Agents | 4 | 2007 | 972 | 0.330 |
Why?
|
Blood Flow Velocity | 8 | 2015 | 1376 | 0.320 |
Why?
|
Prospective Studies | 37 | 2024 | 54950 | 0.320 |
Why?
|
Diabetes Mellitus, Experimental | 6 | 2021 | 1124 | 0.320 |
Why?
|
Ischemia | 6 | 2022 | 1900 | 0.310 |
Why?
|
Metals | 4 | 2016 | 713 | 0.310 |
Why?
|
Time Factors | 44 | 2024 | 40266 | 0.310 |
Why?
|
Cardiomegaly | 1 | 2011 | 591 | 0.310 |
Why?
|
Diltiazem | 6 | 2005 | 132 | 0.300 |
Why?
|
Air Pollutants | 10 | 2014 | 2905 | 0.300 |
Why?
|
Calcium Channel Blockers | 7 | 2013 | 691 | 0.290 |
Why?
|
Treatment Outcome | 29 | 2022 | 65485 | 0.290 |
Why?
|
Oxidative Stress | 4 | 2014 | 3138 | 0.280 |
Why?
|
Motor Vehicles | 2 | 2009 | 280 | 0.280 |
Why?
|
Extracellular Matrix | 2 | 2014 | 1739 | 0.280 |
Why?
|
Physical Exertion | 7 | 1996 | 668 | 0.270 |
Why?
|
Calcium Signaling | 1 | 2011 | 738 | 0.270 |
Why?
|
Valine | 1 | 2008 | 410 | 0.270 |
Why?
|
Circadian Rhythm | 11 | 1997 | 2593 | 0.270 |
Why?
|
Antioxidants | 2 | 2005 | 1673 | 0.270 |
Why?
|
Hypertension | 8 | 2021 | 8615 | 0.260 |
Why?
|
Aortic Valve | 2 | 2021 | 1969 | 0.260 |
Why?
|
Calcinosis | 2 | 2021 | 1481 | 0.260 |
Why?
|
Particulate Matter | 6 | 2010 | 2607 | 0.260 |
Why?
|
Simvastatin | 1 | 2008 | 346 | 0.260 |
Why?
|
Ventricular Remodeling | 2 | 2010 | 1282 | 0.250 |
Why?
|
Diabetes Mellitus | 5 | 2018 | 5892 | 0.250 |
Why?
|
Aortic Valve Stenosis | 3 | 2021 | 2034 | 0.240 |
Why?
|
Bioprosthesis | 1 | 2009 | 593 | 0.240 |
Why?
|
Antihypertensive Agents | 2 | 2019 | 2026 | 0.240 |
Why?
|
Prognosis | 34 | 2024 | 30044 | 0.240 |
Why?
|
Blood Pressure | 14 | 2019 | 8541 | 0.240 |
Why?
|
Cholesterol, HDL | 6 | 2024 | 1820 | 0.240 |
Why?
|
Tomography, X-Ray Computed | 6 | 2023 | 20776 | 0.230 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2006 | 577 | 0.230 |
Why?
|
Cardiac Imaging Techniques | 2 | 2017 | 281 | 0.230 |
Why?
|
Ascorbic Acid | 2 | 2005 | 658 | 0.230 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2007 | 706 | 0.230 |
Why?
|
Carbon | 3 | 2009 | 672 | 0.220 |
Why?
|
Propranolol | 5 | 1993 | 493 | 0.220 |
Why?
|
Swine | 8 | 2020 | 5998 | 0.210 |
Why?
|
Vitamin E | 2 | 2005 | 874 | 0.210 |
Why?
|
Atenolol | 4 | 2000 | 99 | 0.210 |
Why?
|
Occupational Diseases | 1 | 2011 | 1458 | 0.210 |
Why?
|
Double-Blind Method | 19 | 2017 | 12469 | 0.210 |
Why?
|
Benchmarking | 2 | 2019 | 1058 | 0.210 |
Why?
|
Blood Glucose | 3 | 2024 | 6434 | 0.200 |
Why?
|
Myocytes, Cardiac | 1 | 2011 | 1682 | 0.200 |
Why?
|
Tetrazoles | 1 | 2008 | 923 | 0.200 |
Why?
|
Carotid Artery Diseases | 2 | 2021 | 878 | 0.200 |
Why?
|
Heart Valve Prosthesis | 2 | 2009 | 1468 | 0.200 |
Why?
|
Cardiovascular Agents | 5 | 2017 | 849 | 0.200 |
Why?
|
Ultrasonography | 6 | 2016 | 6001 | 0.190 |
Why?
|
Random Allocation | 12 | 2018 | 2396 | 0.190 |
Why?
|
Stroke | 2 | 2023 | 9756 | 0.190 |
Why?
|
Food, Formulated | 1 | 2002 | 103 | 0.190 |
Why?
|
Heart | 5 | 2023 | 4448 | 0.190 |
Why?
|
Carotid Arteries | 3 | 2016 | 943 | 0.190 |
Why?
|
Japan | 2 | 2016 | 1418 | 0.190 |
Why?
|
Vasodilation | 4 | 2015 | 967 | 0.180 |
Why?
|
Severity of Illness Index | 15 | 2024 | 15955 | 0.180 |
Why?
|
Syndrome | 5 | 2021 | 3274 | 0.180 |
Why?
|
Death, Sudden | 5 | 1990 | 301 | 0.180 |
Why?
|
Membrane Glycoproteins | 1 | 2011 | 3714 | 0.180 |
Why?
|
Brachial Artery | 3 | 2015 | 373 | 0.180 |
Why?
|
Drug Therapy, Combination | 15 | 2015 | 6320 | 0.170 |
Why?
|
Dyslipidemias | 2 | 2019 | 873 | 0.170 |
Why?
|
Coronary Vasospasm | 4 | 1983 | 81 | 0.170 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2015 | 2763 | 0.170 |
Why?
|
Fibrinolytic Agents | 4 | 2006 | 2080 | 0.170 |
Why?
|
Prosthesis Failure | 2 | 2019 | 1209 | 0.170 |
Why?
|
C-Reactive Protein | 5 | 2010 | 3858 | 0.170 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2020 | 111 | 0.170 |
Why?
|
Cardiovascular Diseases | 9 | 2007 | 15662 | 0.170 |
Why?
|
Inflammation | 6 | 2022 | 10869 | 0.170 |
Why?
|
Nitroglycerin | 5 | 2006 | 332 | 0.160 |
Why?
|
Prosthesis Design | 3 | 2019 | 2126 | 0.160 |
Why?
|
Hypercholesterolemia | 3 | 2021 | 1145 | 0.160 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2009 | 1568 | 0.160 |
Why?
|
Cardiotonic Agents | 1 | 2002 | 544 | 0.160 |
Why?
|
Animals | 21 | 2021 | 169408 | 0.150 |
Why?
|
Lipids | 5 | 2022 | 3345 | 0.150 |
Why?
|
Thrombolytic Therapy | 6 | 2002 | 2053 | 0.150 |
Why?
|
Triglycerides | 5 | 2020 | 2464 | 0.150 |
Why?
|
Arginine | 1 | 2002 | 932 | 0.150 |
Why?
|
Receptors, LDL | 1 | 2020 | 492 | 0.150 |
Why?
|
Nadolol | 2 | 1994 | 29 | 0.150 |
Why?
|
Activities of Daily Living | 3 | 1999 | 2433 | 0.140 |
Why?
|
Lipoproteins, LDL | 2 | 2014 | 643 | 0.140 |
Why?
|
Vascular Resistance | 2 | 2013 | 939 | 0.140 |
Why?
|
Pilot Projects | 11 | 2017 | 8742 | 0.140 |
Why?
|
Sus scrofa | 3 | 2021 | 430 | 0.140 |
Why?
|
Sirolimus | 2 | 2016 | 1540 | 0.140 |
Why?
|
Europe | 3 | 2018 | 3441 | 0.140 |
Why?
|
Cross-Over Studies | 4 | 2017 | 2108 | 0.130 |
Why?
|
Lipid Metabolism | 1 | 2005 | 1904 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 12252 | 0.130 |
Why?
|
Coronary Artery Bypass | 7 | 2001 | 2194 | 0.130 |
Why?
|
Cheyne-Stokes Respiration | 1 | 2016 | 38 | 0.130 |
Why?
|
Arousal | 3 | 1999 | 1183 | 0.130 |
Why?
|
Telemetry | 1 | 2017 | 200 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2020 | 1246 | 0.130 |
Why?
|
Hyperglycemia | 1 | 2024 | 1389 | 0.130 |
Why?
|
Follow-Up Studies | 20 | 2018 | 39394 | 0.130 |
Why?
|
Sleep Apnea, Central | 1 | 2016 | 88 | 0.120 |
Why?
|
Mechanotransduction, Cellular | 1 | 2019 | 542 | 0.120 |
Why?
|
Hemorheology | 2 | 2007 | 144 | 0.120 |
Why?
|
Indocyanine Green | 1 | 2016 | 239 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2019 | 10397 | 0.120 |
Why?
|
Spectroscopy, Near-Infrared | 2 | 2017 | 752 | 0.120 |
Why?
|
Angina Pectoris, Variant | 5 | 2002 | 53 | 0.110 |
Why?
|
Pravastatin | 3 | 2015 | 393 | 0.110 |
Why?
|
Thrombophilia | 2 | 2015 | 308 | 0.110 |
Why?
|
Heart Conduction System | 3 | 2009 | 1009 | 0.110 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 2714 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 1514 | 0.110 |
Why?
|
Hyperlipidemias | 3 | 2015 | 773 | 0.110 |
Why?
|
Mental Processes | 1 | 1994 | 247 | 0.110 |
Why?
|
Rest | 2 | 1997 | 951 | 0.110 |
Why?
|
Logistic Models | 9 | 2016 | 13317 | 0.110 |
Why?
|
Hypolipidemic Agents | 3 | 2005 | 609 | 0.100 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2015 | 285 | 0.100 |
Why?
|
Galvanic Skin Response | 1 | 1994 | 359 | 0.100 |
Why?
|
Adult | 37 | 2020 | 223818 | 0.100 |
Why?
|
Muscle, Smooth, Vascular | 2 | 2013 | 1493 | 0.100 |
Why?
|
Aged, 80 and over | 18 | 2021 | 59738 | 0.100 |
Why?
|
NF-kappa B | 1 | 2020 | 2492 | 0.100 |
Why?
|
Creatine Kinase | 10 | 1989 | 685 | 0.100 |
Why?
|
Blood Volume | 1 | 2013 | 546 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2016 | 1195 | 0.090 |
Why?
|
Life Support Systems | 1 | 2010 | 11 | 0.090 |
Why?
|
Cathepsin K | 1 | 2011 | 65 | 0.090 |
Why?
|
Diastole | 4 | 2017 | 784 | 0.090 |
Why?
|
Ventricular Dysfunction, Left | 2 | 1999 | 2145 | 0.090 |
Why?
|
Pyridines | 4 | 1983 | 2896 | 0.090 |
Why?
|
Particle Size | 5 | 2009 | 1652 | 0.090 |
Why?
|
Ticlopidine | 1 | 2015 | 730 | 0.090 |
Why?
|
Enzyme Induction | 1 | 2011 | 455 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2892 | 0.090 |
Why?
|
Constriction, Pathologic | 3 | 2023 | 1104 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2010 | 10778 | 0.090 |
Why?
|
Hypoxia, Brain | 1 | 2010 | 139 | 0.090 |
Why?
|
Clinical Trials as Topic | 11 | 2013 | 8055 | 0.080 |
Why?
|
DNA Damage | 1 | 2020 | 2472 | 0.080 |
Why?
|
Cathepsins | 1 | 2011 | 242 | 0.080 |
Why?
|
Treatment Failure | 3 | 2002 | 2663 | 0.080 |
Why?
|
Fibrosis | 3 | 2018 | 2081 | 0.080 |
Why?
|
Dental Care for Disabled | 1 | 1989 | 21 | 0.080 |
Why?
|
Anticoagulants | 2 | 2003 | 4850 | 0.080 |
Why?
|
Vascular Patency | 2 | 2003 | 917 | 0.080 |
Why?
|
Sex Factors | 10 | 2020 | 10641 | 0.080 |
Why?
|
Uric Acid | 1 | 2015 | 806 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2665 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2021 | 2297 | 0.080 |
Why?
|
Nitrates | 3 | 2006 | 260 | 0.080 |
Why?
|
Cardiology | 1 | 2020 | 1701 | 0.080 |
Why?
|
Multivariate Analysis | 7 | 2018 | 12093 | 0.080 |
Why?
|
Environmental Exposure | 3 | 2014 | 4538 | 0.080 |
Why?
|
Glucuronidase | 1 | 2010 | 205 | 0.080 |
Why?
|
Patient Selection | 2 | 2010 | 4265 | 0.080 |
Why?
|
Heparin | 3 | 2006 | 1636 | 0.080 |
Why?
|
Reproducibility of Results | 7 | 2024 | 20244 | 0.080 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 703 | 0.080 |
Why?
|
Metoprolol | 1 | 1989 | 90 | 0.080 |
Why?
|
Monitoring, Physiologic | 4 | 2010 | 1796 | 0.080 |
Why?
|
Tunica Intima | 1 | 2011 | 459 | 0.080 |
Why?
|
Workload | 2 | 2004 | 852 | 0.080 |
Why?
|
Platelet Aggregation | 2 | 1989 | 769 | 0.080 |
Why?
|
Calcium | 1 | 2021 | 5792 | 0.080 |
Why?
|
Fluorescent Dyes | 1 | 2016 | 1933 | 0.080 |
Why?
|
Radionuclide Imaging | 3 | 2011 | 1998 | 0.080 |
Why?
|
Hydrodynamics | 2 | 2020 | 167 | 0.070 |
Why?
|
Arteriosclerosis | 3 | 2003 | 1056 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2016 | 9081 | 0.070 |
Why?
|
Calcium Channels | 1 | 2011 | 624 | 0.070 |
Why?
|
Linear Models | 4 | 2018 | 5890 | 0.070 |
Why?
|
Maximum Allowable Concentration | 1 | 2007 | 64 | 0.070 |
Why?
|
Death, Sudden, Cardiac | 4 | 2020 | 1568 | 0.070 |
Why?
|
Ventricular Function, Left | 3 | 2017 | 3941 | 0.070 |
Why?
|
Aspirin | 2 | 2015 | 3135 | 0.070 |
Why?
|
Disease Models, Animal | 4 | 2016 | 18366 | 0.070 |
Why?
|
Nitric Oxide | 2 | 2007 | 2149 | 0.070 |
Why?
|
Counterpulsation | 1 | 2006 | 16 | 0.070 |
Why?
|
Recurrence | 11 | 2019 | 8512 | 0.070 |
Why?
|
Medical Errors | 2 | 2005 | 1262 | 0.070 |
Why?
|
Autonomic Nervous System | 2 | 2006 | 709 | 0.070 |
Why?
|
Helminth Proteins | 1 | 2007 | 173 | 0.070 |
Why?
|
Cholesterol | 2 | 1995 | 2913 | 0.070 |
Why?
|
Plasminogen Activators | 2 | 1997 | 199 | 0.060 |
Why?
|
Republic of Korea | 2 | 2018 | 592 | 0.060 |
Why?
|
Dietary Fats | 2 | 2011 | 2003 | 0.060 |
Why?
|
Thrombosis | 2 | 2019 | 2956 | 0.060 |
Why?
|
Case-Control Studies | 6 | 2022 | 22294 | 0.060 |
Why?
|
Retrospective Studies | 12 | 2023 | 81892 | 0.060 |
Why?
|
Mechanoreceptors | 1 | 2007 | 194 | 0.060 |
Why?
|
Elastic Tissue | 1 | 2005 | 66 | 0.060 |
Why?
|
Medical History Taking | 1 | 1989 | 779 | 0.060 |
Why?
|
Hypothermia, Induced | 1 | 2010 | 756 | 0.060 |
Why?
|
Ventricular Dysfunction | 1 | 2006 | 144 | 0.060 |
Why?
|
Endocarditis, Bacterial | 1 | 1989 | 436 | 0.060 |
Why?
|
Therapeutics | 1 | 2005 | 113 | 0.060 |
Why?
|
Odds Ratio | 2 | 2015 | 9682 | 0.060 |
Why?
|
Isoenzymes | 10 | 1989 | 1687 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9549 | 0.060 |
Why?
|
North America | 2 | 2018 | 1290 | 0.060 |
Why?
|
Vasomotor System | 1 | 2005 | 208 | 0.060 |
Why?
|
Exercise Tolerance | 2 | 2017 | 846 | 0.060 |
Why?
|
Cohort Studies | 9 | 2022 | 41800 | 0.060 |
Why?
|
Air Pollutants, Occupational | 1 | 2006 | 406 | 0.060 |
Why?
|
Brazil | 2 | 2018 | 1249 | 0.060 |
Why?
|
Diet Therapy | 1 | 2005 | 150 | 0.060 |
Why?
|
Automobile Driving | 1 | 2009 | 442 | 0.060 |
Why?
|
Personnel Staffing and Scheduling | 2 | 2004 | 497 | 0.060 |
Why?
|
Sympathetic Nervous System | 1 | 1987 | 521 | 0.060 |
Why?
|
Enoxaparin | 1 | 2006 | 391 | 0.060 |
Why?
|
Work Schedule Tolerance | 2 | 2004 | 553 | 0.060 |
Why?
|
Internationality | 2 | 2021 | 1008 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4207 | 0.050 |
Why?
|
Antithrombins | 1 | 2006 | 294 | 0.050 |
Why?
|
United States | 9 | 2022 | 73180 | 0.050 |
Why?
|
Blood Viscosity | 1 | 2003 | 125 | 0.050 |
Why?
|
Heart Arrest | 2 | 2010 | 1515 | 0.050 |
Why?
|
Diabetes Complications | 2 | 1989 | 1320 | 0.050 |
Why?
|
Thromboembolism | 1 | 2009 | 1004 | 0.050 |
Why?
|
Environmental Monitoring | 2 | 2010 | 1466 | 0.050 |
Why?
|
Angiotensins | 1 | 2023 | 141 | 0.050 |
Why?
|
Risk | 6 | 2008 | 9621 | 0.050 |
Why?
|
Age Factors | 9 | 2020 | 18454 | 0.050 |
Why?
|
Chronic Disease | 4 | 2006 | 9384 | 0.050 |
Why?
|
Body Mass Index | 2 | 2019 | 13054 | 0.050 |
Why?
|
Hemorrhage | 2 | 2009 | 3465 | 0.050 |
Why?
|
Postoperative Hemorrhage | 1 | 2006 | 420 | 0.050 |
Why?
|
Dust | 1 | 2005 | 488 | 0.050 |
Why?
|
Necrosis | 2 | 2018 | 1621 | 0.050 |
Why?
|
Organotechnetium Compounds | 1 | 2002 | 133 | 0.050 |
Why?
|
Rabbits | 1 | 2008 | 4774 | 0.050 |
Why?
|
Iatrogenic Disease | 1 | 2005 | 552 | 0.050 |
Why?
|
Lovastatin | 1 | 2002 | 115 | 0.050 |
Why?
|
Verapamil | 2 | 2000 | 242 | 0.050 |
Why?
|
Carbon Monoxide | 1 | 2005 | 552 | 0.050 |
Why?
|
Risk Management | 1 | 2005 | 558 | 0.050 |
Why?
|
Boston | 6 | 2017 | 9375 | 0.050 |
Why?
|
Acute Disease | 4 | 2006 | 7245 | 0.050 |
Why?
|
Hostility | 1 | 2022 | 185 | 0.050 |
Why?
|
Renin | 1 | 2023 | 648 | 0.050 |
Why?
|
Organophosphorus Compounds | 1 | 2002 | 211 | 0.050 |
Why?
|
Attention | 2 | 2004 | 2425 | 0.050 |
Why?
|
Systole | 2 | 2004 | 937 | 0.050 |
Why?
|
Chronotherapy | 1 | 2000 | 11 | 0.050 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 325 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 2 | 1997 | 1165 | 0.040 |
Why?
|
Clinical Protocols | 2 | 2019 | 1445 | 0.040 |
Why?
|
Defibrillators, Implantable | 1 | 2009 | 1498 | 0.040 |
Why?
|
Radionuclide Ventriculography | 1 | 1999 | 40 | 0.040 |
Why?
|
Practice Guidelines as Topic | 4 | 2010 | 7460 | 0.040 |
Why?
|
Thallium Radioisotopes | 1 | 1999 | 139 | 0.040 |
Why?
|
Anger | 1 | 2022 | 405 | 0.040 |
Why?
|
Body Surface Area | 1 | 2020 | 206 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2000 | 387 | 0.040 |
Why?
|
Phenotype | 2 | 2017 | 16735 | 0.040 |
Why?
|
MicroRNAs | 1 | 2015 | 3811 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2023 | 736 | 0.040 |
Why?
|
Longitudinal Studies | 4 | 2019 | 14795 | 0.040 |
Why?
|
Aldosterone | 1 | 2023 | 881 | 0.040 |
Why?
|
Biology | 1 | 2020 | 292 | 0.040 |
Why?
|
Regeneration | 1 | 2007 | 1524 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2005 | 1495 | 0.040 |
Why?
|
Survival Rate | 6 | 2010 | 12873 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2010 | 3411 | 0.040 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2007 | 1106 | 0.040 |
Why?
|
Multicenter Studies as Topic | 5 | 2006 | 1737 | 0.040 |
Why?
|
Intensive Care Units | 3 | 2005 | 3800 | 0.040 |
Why?
|
Counseling | 1 | 2005 | 1554 | 0.040 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 5176 | 0.040 |
Why?
|
Autonomic Nervous System Diseases | 2 | 2010 | 268 | 0.030 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 1141 | 0.030 |
Why?
|
Heart Diseases | 2 | 2006 | 2819 | 0.030 |
Why?
|
Absorbable Implants | 1 | 2019 | 338 | 0.030 |
Why?
|
Anxiety | 2 | 2009 | 4677 | 0.030 |
Why?
|
Heart Failure | 7 | 2008 | 11879 | 0.030 |
Why?
|
Cardiomyopathies | 1 | 2008 | 2057 | 0.030 |
Why?
|
Occupational Exposure | 1 | 2006 | 1807 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2020 | 997 | 0.030 |
Why?
|
Catecholamines | 1 | 1996 | 390 | 0.030 |
Why?
|
HLA Antigens | 1 | 1981 | 1336 | 0.030 |
Why?
|
Oscillometry | 1 | 2016 | 150 | 0.030 |
Why?
|
Problem Solving | 1 | 1998 | 443 | 0.030 |
Why?
|
Cholestyramine Resin | 1 | 1994 | 25 | 0.030 |
Why?
|
Gemfibrozil | 1 | 1994 | 30 | 0.030 |
Why?
|
Combined Modality Therapy | 4 | 1996 | 8559 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2020 | 14485 | 0.030 |
Why?
|
Oxygen | 1 | 2006 | 4273 | 0.030 |
Why?
|
Life Style | 1 | 2006 | 3931 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2357 | 0.030 |
Why?
|
Sex Characteristics | 2 | 2020 | 2660 | 0.030 |
Why?
|
Internship and Residency | 2 | 2004 | 5956 | 0.030 |
Why?
|
Incidence | 3 | 2009 | 21545 | 0.030 |
Why?
|
Peptides | 1 | 2006 | 4353 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2016 | 1379 | 0.030 |
Why?
|
Heart Atria | 1 | 2020 | 1360 | 0.030 |
Why?
|
Niacin | 1 | 1994 | 117 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2006 | 5150 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2020 | 1197 | 0.030 |
Why?
|
Drug Administration Schedule | 3 | 2007 | 4862 | 0.030 |
Why?
|
Platelet Function Tests | 1 | 2015 | 275 | 0.030 |
Why?
|
Kidney | 2 | 2021 | 7057 | 0.030 |
Why?
|
Thermodilution | 1 | 2013 | 50 | 0.030 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2003 | 1459 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2003 | 2240 | 0.030 |
Why?
|
Protein Kinases | 1 | 2020 | 1611 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 548 | 0.030 |
Why?
|
Heart Murmurs | 2 | 1990 | 92 | 0.030 |
Why?
|
Shock, Cardiogenic | 2 | 1989 | 711 | 0.030 |
Why?
|
Humidity | 1 | 2014 | 207 | 0.030 |
Why?
|
Aorta | 1 | 2020 | 2046 | 0.030 |
Why?
|
Adipose Tissue | 2 | 2022 | 3335 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2021 | 1752 | 0.020 |
Why?
|
Statistics as Topic | 2 | 1996 | 2359 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2003 | 5323 | 0.020 |
Why?
|
Depression | 2 | 2009 | 8240 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 3438 | 0.020 |
Why?
|
Consensus | 2 | 2017 | 3214 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14751 | 0.020 |
Why?
|
Comorbidity | 3 | 2016 | 10591 | 0.020 |
Why?
|
Heart Ventricles | 4 | 2020 | 3840 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2002 | 2008 | 0.020 |
Why?
|
Seasons | 2 | 2014 | 1523 | 0.020 |
Why?
|
Clinical Enzyme Tests | 2 | 1988 | 114 | 0.020 |
Why?
|
Fluorescein Angiography | 1 | 2017 | 1086 | 0.020 |
Why?
|
Ambulatory Care | 3 | 1994 | 2783 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1645 | 0.020 |
Why?
|
Drug Synergism | 1 | 2015 | 1762 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 3253 | 0.020 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2017 | 672 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2000 | 1813 | 0.020 |
Why?
|
Cost of Illness | 1 | 2021 | 1959 | 0.020 |
Why?
|
Exercise | 3 | 2021 | 5953 | 0.020 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2010 | 111 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2021 | 11934 | 0.020 |
Why?
|
Sleep Deprivation | 3 | 2004 | 848 | 0.020 |
Why?
|
Obesity | 2 | 2015 | 13087 | 0.020 |
Why?
|
Manifest Anxiety Scale | 1 | 2009 | 7 | 0.020 |
Why?
|
Analysis of Variance | 4 | 1995 | 6242 | 0.020 |
Why?
|
Hospitalization | 8 | 2008 | 10845 | 0.020 |
Why?
|
False Negative Reactions | 3 | 1988 | 575 | 0.020 |
Why?
|
Heart Rupture | 1 | 1989 | 21 | 0.020 |
Why?
|
Heart Rupture, Post-Infarction | 1 | 1989 | 48 | 0.020 |
Why?
|
Algorithms | 3 | 2020 | 14199 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2002 | 3442 | 0.020 |
Why?
|
Sleep | 1 | 2004 | 4820 | 0.020 |
Why?
|
Evaluation Studies as Topic | 2 | 1988 | 1629 | 0.020 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2010 | 462 | 0.020 |
Why?
|
False Positive Reactions | 3 | 1988 | 963 | 0.020 |
Why?
|
Rheumatic Heart Disease | 1 | 1989 | 164 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 1988 | 372 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5216 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1886 | 0.020 |
Why?
|
Mitral Valve Prolapse | 1 | 1989 | 213 | 0.020 |
Why?
|
Signal Transduction | 2 | 2021 | 23652 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3629 | 0.020 |
Why?
|
Reference Values | 1 | 1994 | 4941 | 0.020 |
Why?
|
Pericarditis | 1 | 1989 | 136 | 0.020 |
Why?
|
Internal Medicine | 2 | 2004 | 1064 | 0.020 |
Why?
|
Temperature | 1 | 2014 | 2235 | 0.020 |
Why?
|
Missouri | 1 | 2007 | 113 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2007 | 6512 | 0.020 |
Why?
|
Coma | 1 | 2010 | 487 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2228 | 0.020 |
Why?
|
Age of Onset | 1 | 1994 | 3346 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 1999 | 13020 | 0.020 |
Why?
|
Recovery of Function | 1 | 2017 | 2990 | 0.020 |
Why?
|
Personality Inventory | 1 | 2009 | 1018 | 0.020 |
Why?
|
Bundle-Branch Block | 1 | 1988 | 278 | 0.020 |
Why?
|
Evidence-Based Practice | 1 | 2010 | 500 | 0.020 |
Why?
|
Prevalence | 3 | 2018 | 15875 | 0.020 |
Why?
|
Welding | 1 | 2006 | 89 | 0.020 |
Why?
|
Sulfur Dioxide | 1 | 2006 | 178 | 0.020 |
Why?
|
Stroke Volume | 6 | 1991 | 5621 | 0.020 |
Why?
|
Death Certificates | 1 | 1987 | 172 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2010 | 1169 | 0.020 |
Why?
|
Ohio | 1 | 2006 | 321 | 0.020 |
Why?
|
Fatty Acids, Omega-3 | 1 | 1995 | 1399 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5800 | 0.020 |
Why?
|
Digoxin | 1 | 1986 | 246 | 0.020 |
Why?
|
Educational Status | 1 | 1993 | 2515 | 0.020 |
Why?
|
Soot | 1 | 2007 | 219 | 0.020 |
Why?
|
Hirudins | 1 | 2006 | 179 | 0.020 |
Why?
|
Tachycardia | 1 | 1987 | 599 | 0.020 |
Why?
|
Women | 1 | 1987 | 225 | 0.020 |
Why?
|
Meteorological Concepts | 1 | 2004 | 30 | 0.020 |
Why?
|
Truth Disclosure | 1 | 2009 | 433 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2002 | 5520 | 0.010 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 937 | 0.010 |
Why?
|
Ventricular Fibrillation | 1 | 1987 | 537 | 0.010 |
Why?
|
Societies, Medical | 1 | 2017 | 3967 | 0.010 |
Why?
|
Sinoatrial Node | 1 | 1985 | 99 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 1997 | 12563 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 899 | 0.010 |
Why?
|
Heart Block | 1 | 1986 | 390 | 0.010 |
Why?
|
Echocardiography | 1 | 2017 | 5046 | 0.010 |
Why?
|
Benzofurans | 1 | 1985 | 139 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10486 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3421 | 0.010 |
Why?
|
Disability Evaluation | 1 | 1991 | 1839 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8664 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2010 | 1315 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2931 | 0.010 |
Why?
|
Oxygen Consumption | 1 | 1990 | 1883 | 0.010 |
Why?
|
Amiodarone | 1 | 1985 | 217 | 0.010 |
Why?
|
Mice | 2 | 2020 | 82074 | 0.010 |
Why?
|
Nitrogen Dioxide | 1 | 2006 | 533 | 0.010 |
Why?
|
Psychological Tests | 1 | 2005 | 642 | 0.010 |
Why?
|
Smoking | 3 | 2015 | 9094 | 0.010 |
Why?
|
Self-Assessment | 1 | 2005 | 400 | 0.010 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2010 | 997 | 0.010 |
Why?
|
Benzazepines | 1 | 1985 | 309 | 0.010 |
Why?
|
Ozone | 1 | 2006 | 496 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2007 | 2231 | 0.010 |
Why?
|
Bronchodilator Agents | 1 | 2006 | 518 | 0.010 |
Why?
|
Probability | 2 | 1987 | 2483 | 0.010 |
Why?
|
Hypotension | 2 | 1986 | 888 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1989 | 1486 | 0.010 |
Why?
|
Vasoconstriction | 1 | 2004 | 593 | 0.010 |
Why?
|
Melatonin | 1 | 2007 | 670 | 0.010 |
Why?
|
Air Pollution, Indoor | 1 | 2009 | 918 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2010 | 1890 | 0.010 |
Why?
|
Substance Withdrawal Syndrome | 1 | 1986 | 628 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 2006 | 1832 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 13048 | 0.010 |
Why?
|
Coronary Care Units | 1 | 1982 | 235 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6673 | 0.010 |
Why?
|
Mitral Valve Insufficiency | 1 | 1990 | 1415 | 0.010 |
Why?
|
Quality of Life | 1 | 2002 | 13510 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 2862 | 0.010 |
Why?
|
Remission Induction | 2 | 1995 | 2411 | 0.010 |
Why?
|
Twins | 1 | 1981 | 340 | 0.010 |
Why?
|
Medication Errors | 1 | 2005 | 784 | 0.010 |
Why?
|
Postoperative Complications | 2 | 2015 | 15889 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2006 | 1162 | 0.010 |
Why?
|
Myocardium | 3 | 2003 | 4790 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2005 | 2742 | 0.010 |
Why?
|
Polysomnography | 1 | 2004 | 1871 | 0.010 |
Why?
|
Exercise Therapy | 1 | 2004 | 938 | 0.010 |
Why?
|
Placebos | 2 | 1996 | 1668 | 0.010 |
Why?
|
Canada | 1 | 2002 | 2129 | 0.010 |
Why?
|
Troponin I | 1 | 2001 | 662 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2003 | 1794 | 0.010 |
Why?
|
Health Surveys | 1 | 2006 | 4055 | 0.010 |
Why?
|
Delayed-Action Preparations | 1 | 2000 | 969 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2003 | 1541 | 0.010 |
Why?
|
Clostridium perfringens | 1 | 1976 | 29 | 0.010 |
Why?
|
Phospholipases | 1 | 1976 | 75 | 0.010 |
Why?
|
Diphosphates | 2 | 1986 | 89 | 0.010 |
Why?
|
Insulin | 1 | 1989 | 6610 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 1986 | 1947 | 0.010 |
Why?
|
Isosorbide Dinitrate | 1 | 1994 | 34 | 0.010 |
Why?
|
Plant Oils | 1 | 1995 | 199 | 0.010 |
Why?
|
Information Systems | 1 | 1996 | 400 | 0.010 |
Why?
|
Norepinephrine | 1 | 1996 | 900 | 0.010 |
Why?
|
Adolescent | 3 | 2007 | 89247 | 0.010 |
Why?
|
Dietary Fats, Unsaturated | 1 | 1995 | 223 | 0.010 |
Why?
|
Massachusetts | 1 | 1987 | 8888 | 0.010 |
Why?
|
Epinephrine | 1 | 1996 | 794 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1981 | 4624 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2002 | 2734 | 0.010 |
Why?
|
Lipoproteins | 1 | 1995 | 880 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5544 | 0.010 |
Why?
|
Health Care Costs | 1 | 2003 | 3270 | 0.010 |
Why?
|
Clostridium Infections | 1 | 1976 | 559 | 0.000 |
Why?
|
Survival Analysis | 1 | 2000 | 10115 | 0.000 |
Why?
|
Heart Septum | 1 | 1989 | 304 | 0.000 |
Why?
|
Mass Screening | 1 | 2003 | 5455 | 0.000 |
Why?
|
Fatty Acids | 1 | 1995 | 1812 | 0.000 |
Why?
|
Heart Function Tests | 1 | 1987 | 317 | 0.000 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 1986 | 52 | 0.000 |
Why?
|
Technetium | 1 | 1986 | 326 | 0.000 |
Why?
|
Reoperation | 1 | 1995 | 4342 | 0.000 |
Why?
|
Bradycardia | 1 | 1986 | 305 | 0.000 |
Why?
|
Eating | 1 | 1990 | 1542 | 0.000 |
Why?
|
Regression Analysis | 1 | 1992 | 6346 | 0.000 |
Why?
|
Sepsis | 1 | 1976 | 2609 | 0.000 |
Why?
|
Patient Readmission | 1 | 1995 | 3313 | 0.000 |
Why?
|
Databases, Factual | 1 | 1996 | 8095 | 0.000 |
Why?
|
Drug Interactions | 1 | 1985 | 1421 | 0.000 |
Why?
|
Myocardial Contraction | 1 | 1985 | 1526 | 0.000 |
Why?
|
Pregnancy | 1 | 1981 | 30175 | 0.000 |
Why?
|
Kidney Diseases | 1 | 1988 | 2100 | 0.000 |
Why?
|
Chromatography, Thin Layer | 1 | 1976 | 212 | 0.000 |
Why?
|
Diglycerides | 1 | 1976 | 176 | 0.000 |
Why?
|
Anemia, Hemolytic | 1 | 1976 | 164 | 0.000 |
Why?
|
Patient Admission | 1 | 1982 | 1369 | 0.000 |
Why?
|
Anemia, Aplastic | 1 | 1976 | 231 | 0.000 |
Why?
|
Patient Compliance | 1 | 1984 | 2701 | 0.000 |
Why?
|
Length of Stay | 1 | 1982 | 6525 | 0.000 |
Why?
|